MHRP is dedicated to developing a safe and globally effective HIV vaccine to protect our Armed Forces wherever they may be deployed.
The Army-led RV144 “Thai Study” was the first clinical trial to show modest efficacy in preventing HIV infection. Study results showed that a preventive HIV vaccine is possible, and the landmark trial continues to provide scientific direction to help guide vaccine development and testing.
Planning for the Future
MHRP's ongoing work spans a continuum of research from basic and preclinical science, through Phase 1 development and more advanced efficacy trials.
MHRP is pursuing new immunogens and delivery platforms, which, combined with a more powerful adjuvant the Army has already developed, have the potential to generate broadly neutralizing antibodies to effectively prevent HIV.
MHRP scientists are pursuing a variety other innovative products and strategies to approach the complex interactions between HIV and the immune system from many angles. Researchers are testing a novel adjuvant developed by MHRP scientists, called the Army Liposome Formulation (ALF), and an experimental combination HIV-heroin vaccine is advancing through safety studies. Other planned studies will examine the effects of rapid dose administration and fractional dosing.